S
NVAX icon

Sanofi’s Novavax NVAX Stock Holding History

Sanofi’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$56M Hold
6,880,481
– – 16.67% 3
2025
Q4 		$46.2M Hold
6,880,481
– – 14.9% 3
2025
Q3 		$59.7M Hold
6,880,481
– – 22.91% 2
2025
Q2 		$43.3M Hold
6,880,481
– – 24.67% 2
2025
Q1 		$44.1M Hold
6,880,481
– – 26.58% 2
2024
Q4 		$55.3M Buy
+6,880,481
New +$66.3M 31.73% 2

Other funds holding NVAX

SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Sanofi's NVAX Position: Q1 2026 in Review

Sanofi held its Novavax (NVAX) position steady in Q1 2026 at 6,880,481 shares worth $56M. The position accounts for 16.67% of the portfolio, ranked #3.

Sanofi first reported a position in NVAX in Q4 2024 and has held it in 6 quarters since. The position peaked at $59.7M in Q3 2025. 257 funds tracked by Wall St. Rank hold NVAX as of Q1 2026.

  • Sanofi held 6,880,481 shares of Novavax worth $56M as of Q1 2026.
  • Sanofi left its Novavax share count unchanged in Q1 2026.
  • Novavax made up 16.67% of Sanofi's portfolio in Q1 2026, its #3 holding.
  • Sanofi first reported a position in Novavax in Q4 2024 and has held it in 6 quarters since.
  • Sanofi's Novavax position peaked at $59.7M in Q3 2025.
  • 257 funds tracked by Wall St. Rank held Novavax as of Q1 2026.

Based on Sanofi's 13F filing for Q1 2026, filed 7 May 2026.